Do analysts recommend KOO or INS?

Kooth currently has a consensus target price of GBX 330, indicating a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, equities research analysts plainly believe Kooth is more favorable than Instem. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Instem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, KOO or INS?

Kooth has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kooth £63.29M 0.93 £4.00M £7.00 23.14 Instem £61.63M 0.00 £3.34M £0.14 N/A

Is KOO or INS more profitable?

Instem has a net margin of 5.50% compared to Kooth's net margin of 4.12%. Kooth's return on equity of 8.84% beat Instem's return on equity. Company Net Margins Return on Equity Return on Assets Kooth 4.12% 8.84% 10.12% Instem 5.50% 6.35% 4.62%

Do analysts prefer INHC or KOO?

Kooth has a consensus target price of GBX 330, suggesting a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, analysts clearly believe Kooth is more favorable than Induction Healthcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Induction Healthcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate RENX or KOO?

Kooth has a consensus target price of GBX 330, indicating a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, analysts clearly believe Kooth is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, RENX or KOO?

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Renalytix £3.30M 2.33 -£109.93M -£4.00 N/A Kooth £63.29M 0.93 £4.00M £7.00 23.14

Is RENX or KOO more profitable?

Kooth has a net margin of 4.12% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Kooth's return on equity. Company Net Margins Return on Equity Return on Assets Renalytix -680.00% 274.67% -93.54% Kooth 4.12% 8.84% 10.12%

Do analysts prefer KOO or FDBK?

Kooth presently has a consensus price target of GBX 330, suggesting a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, analysts clearly believe Kooth is more favorable than Feedback. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Feedback 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, KOO or FDBK?

Kooth has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kooth £63.29M 0.93 £4.00M £7.00 23.14 Feedback £849.62K 4.02 -£10.84M -£15.74 N/A

Is KOO or FDBK more profitable?

Kooth has a net margin of 4.12% compared to Feedback's net margin of -845.25%. Kooth's return on equity of 8.84% beat Feedback's return on equity. Company Net Margins Return on Equity Return on Assets Kooth 4.12% 8.84% 10.12% Feedback -845.25% -135.17% -22.99%

Kooth (KOO) Competitors

GBX 160 -7.50 (-4.48%)

As of 08:21 AM Eastern

Compare

KOO vs. INS, COG, INHC, RENX, and FDBK

Should you buy Kooth stock or one of its competitors? MarketBeat compares Kooth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kooth include Instem (INS), Cambridge Cognition (COG), Induction Healthcare Group (INHC), Renalytix (RENX), and Feedback (FDBK). These companies are all part of the "health information services" industry.

How does Kooth compare to Instem?

Kooth (LON:KOO) and Instem (LON:INS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Kooth has a beta of 1.238, indicating that its share price is 24% more volatile than the broader market. Comparatively, Instem has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

21.7% of Kooth shares are held by institutional investors. Comparatively, 65.9% of Instem shares are held by institutional investors. 30.6% of Kooth shares are held by company insiders. Comparatively, 30.0% of Instem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kooth has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.93	£4.00M	£7.00	23.14
Instem	£61.63M	0.00	£3.34M	£0.14	N/A

In the previous week, Kooth's average media sentiment score of 0.00 equaled Instem'saverage media sentiment score.

Company	Overall Sentiment
Kooth	Neutral
Instem	Neutral

Instem has a net margin of 5.50% compared to Kooth's net margin of 4.12%. Kooth's return on equity of 8.84% beat Instem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Instem	5.50%	6.35%	4.62%

Kooth currently has a consensus target price of GBX 330, indicating a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, equities research analysts plainly believe Kooth is more favorable than Instem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Instem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Kooth beats Instem on 10 of the 13 factors compared between the two stocks.

How does Kooth compare to Cambridge Cognition?

Kooth (LON:KOO) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Cambridge Cognition had 2 more articles in the media than Kooth. MarketBeat recorded 2 mentions for Cambridge Cognition and 0 mentions for Kooth. Cambridge Cognition's average media sentiment score of 0.68 beat Kooth's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company	Overall Sentiment
Kooth	Neutral
Cambridge Cognition	Positive

Kooth has a beta of 1.238, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Kooth presently has a consensus price target of GBX 330, indicating a potential upside of 103.70%. Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 48.94%. Given Kooth's higher probable upside, analysts plainly believe Kooth is more favorable than Cambridge Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.93	£4.00M	£7.00	23.14
Cambridge Cognition	£9.40M	1.86	-£1.58M	-£3.90	N/A

Kooth has a net margin of 4.12% compared to Cambridge Cognition's net margin of -17.82%. Kooth's return on equity of 8.84% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

21.7% of Kooth shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 30.6% of Kooth shares are held by company insiders. Comparatively, 3.4% of Cambridge Cognition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Kooth beats Cambridge Cognition on 12 of the 15 factors compared between the two stocks.

How does Kooth compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Kooth (LON:KOO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 21.7% of Kooth shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by insiders. Comparatively, 30.6% of Kooth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kooth has higher revenue and earnings than Induction Healthcare Group. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A
Kooth	£63.29M	0.93	£4.00M	£7.00	23.14

Kooth has a consensus target price of GBX 330, suggesting a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, analysts clearly believe Kooth is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kooth has a net margin of 4.12% compared to Induction Healthcare Group's net margin of -23.86%. Kooth's return on equity of 8.84% beat Induction Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Induction Healthcare Group	-23.86%	-14.58%	-7.32%
Kooth	4.12%	8.84%	10.12%

Induction Healthcare Group has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market. Comparatively, Kooth has a beta of 1.238, suggesting that its stock price is 24% more volatile than the broader market.

In the previous week, Induction Healthcare Group's average media sentiment score of 0.00 equaled Kooth'saverage media sentiment score.

Company	Overall Sentiment
Induction Healthcare Group	Neutral
Kooth	Neutral

Summary

Kooth beats Induction Healthcare Group on 12 of the 14 factors compared between the two stocks.

How does Kooth compare to Renalytix?

Renalytix (LON:RENX) and Kooth (LON:KOO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Renalytix's average media sentiment score of 0.00 equaled Kooth'saverage media sentiment score.

Company	Overall Sentiment
Renalytix	Neutral
Kooth	Neutral

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	2.33	-£109.93M	-£4.00	N/A
Kooth	£63.29M	0.93	£4.00M	£7.00	23.14

Renalytix has a beta of 1.974, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Kooth has a beta of 1.238, suggesting that its share price is 24% more volatile than the broader market.

14.0% of Renalytix shares are held by institutional investors. Comparatively, 21.7% of Kooth shares are held by institutional investors. 5.1% of Renalytix shares are held by insiders. Comparatively, 30.6% of Kooth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kooth has a net margin of 4.12% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Kooth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
Kooth	4.12%	8.84%	10.12%

Kooth has a consensus target price of GBX 330, indicating a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, analysts clearly believe Kooth is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kooth beats Renalytix on 11 of the 14 factors compared between the two stocks.

How does Kooth compare to Feedback?

Kooth (LON:KOO) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Kooth has a beta of 1.238, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Kooth's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company	Overall Sentiment
Kooth	Neutral
Feedback	Neutral

Kooth presently has a consensus price target of GBX 330, suggesting a potential upside of 103.70%. Given Kooth's stronger consensus rating and higher probable upside, analysts clearly believe Kooth is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.7% of Kooth shares are held by institutional investors. Comparatively, 35.7% of Feedback shares are held by institutional investors. 30.6% of Kooth shares are held by insiders. Comparatively, 8.0% of Feedback shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kooth has a net margin of 4.12% compared to Feedback's net margin of -845.25%. Kooth's return on equity of 8.84% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Feedback	-845.25%	-135.17%	-22.99%

Kooth has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.93	£4.00M	£7.00	23.14
Feedback	£849.62K	4.02	-£10.84M	-£15.74	N/A

Summary

Kooth beats Feedback on 12 of the 14 factors compared between the two stocks.

Get Kooth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOO vs. The Competition

Export

Metric	Kooth	Health Information Services Industry	Medical Sector	LON Exchange
Market Cap	£58.76M	£332.86M	£6.32B	£2.79B
Dividend Yield	N/A	5.59%	2.69%	6.13%
P/E Ratio	23.14	196.23	21.04	364.83
Price / Sales	0.93	129.82	559.52	87,614.39
Price / Cash	5.42	47.14	42.31	27.85
Price / Book	2.51	5.56	9.93	7.83
Net Income	£4.00M	-£22.78M	£3.56B	£5.88B
7 Day Performance	-4.71%	0.99%	-0.44%	6.72%
1 Month Performance	26.07%	0.24%	4.59%	9.93%
1 Year Performance	-7.43%	-10.35%	27.59%	75.98%

Kooth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOO Kooth	2.0792 of 5 stars	GBX 160 -4.5%	GBX 330 +106.3%	-1.5%	£58.03M	£63.29M	22.86	478
INS Instem	N/A	N/A	N/A	N/A	£199.62M	£61.63M	5,928.57	500
COG Cambridge Cognition	1.8541 of 5 stars	GBX 34 flat	GBX 56 +64.7%	-5.1%	£15.83M	£9.40M	N/A	80
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+4.2%	£9.00M	£12.57M	N/A	74
RENX Renalytix	N/A	GBX 1.60 -11.1%	N/A	-75.2%	£7.87M	£3.30M	N/A	102	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:KOO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kooth (KOO) Competitors